MS-275 Chemical Analogues Promote Hemoglobin Production and Erythroid Differentiation of K562 Cells

References

• Modell B, Darlison M. Global epidemiology of haemoglobin disorders and derived service indicators. Bull World Health Organ. 2008;86(6):480–487.
   PubMed Web of Science ®Google Scholar
• Weatherall DJ, Williams TN, Allen SJ, O'Donnell A. The population genetics and dynamics of the thalassemias. Hematol/Oncol Clin North Am. 2010;24(6):1021–1031.
   PubMed Web of Science ®Google Scholar
• Olivieri NF. The β-thalassemias. N Engl J Med. 1999;341(2):99–109.
   PubMed Web of Science ®Google Scholar
• Watson J. The significance of the paucity of sickle cells in newborn Negro infants. Am J Med Sci. 1948;215(4):419–423.
   PubMed Web of Science ®Google Scholar
• Weatherall DJ. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Nat Rev Genet. 2001;2(4):245–255.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Weatherall DJ. The therapeutic reactivation of fetal haemoglobin. Hum Mol Genet. 1998;7(10):1655–1658.
   PubMed Web of Science ®Google Scholar
• Testa U. Fetal hemoglobin chemical inducers for treatment of hemoglobinopathies. Ann Hematol. 2009;88(6):505–528.
   PubMed Web of Science ®Google Scholar
• Theodorou A, Phylactides M, Forti L, et al. The investigation of resveratrol and analogs as potential inducers of fetal hemoglobin. Blood Cells Mol Dis. 2016;58:6–12.
   PubMed Web of Science ®Google Scholar
• Chaneiam N, Changtam C, Mungkongdee T, et al. A reduced curcuminoid analog as a novel inducer of fetal hemoglobin. Ann Hematol. 2013;92(3):379–386.
   PubMed Web of Science ®Google Scholar
• Lampronti I, Bianchi N, Zuccato C, et al. Increase in γ-globin mRNA content in human erythroid cells treated with angelicin analogs. Int J Hematol. 2009;90(3):318–327.
   PubMed Web of Science ®Google Scholar
• Chiarabelli C, Bianchi N, Borgatti M, et al. Induction of γ-globin gene expression by tallimustine analogs in human erythroid cells. Haematologica. 2003;88(7):826–827.
   PubMed Web of Science ®Google Scholar
• Bianchi N, Ongaro F, Chiarabelli C, et al. Induction of erythroid differentiation of human K562 cells by cisplatin analogs. Biochem Pharmacol. 2000;60(1):31–40.
   PubMed Web of Science ®Google Scholar
• Witt O, Monkemeyer S, Ronndahl G, et al. Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. Blood. 2003;101(5):2001–2007.
   PubMed Web of Science ®Google Scholar
• Cao H, Stamatoyannopoulos G. Histone deacetylase inhibitor FK228 is a potent inducer of human fetal hemoglobin. Am J Hematol. 2006;81(12):981–983.
   PubMed Web of Science ®Google Scholar
• Esrick EB, McConkey M, Lin K, et al. Inactivation of HDAC1 or HDAC2 induces gamma globin expression without altering cell cycle or proliferation. Am J Hematol. 2015;90(7):624–628.
   PubMed Web of Science ®Google Scholar
• Renneville A, Van Galen P, Canver MC, et al. EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression. Blood. 2015;126(16):1930–1939.
   PubMed Web of Science ®Google Scholar
• Monneret C. Histone deacetylase inhibitors. Eur J Med Chem. 2005;40(1):1–13.
   PubMed Web of Science ®Google Scholar
• Itoh Y, Suzuki T, Miyata N. Isoform-selective histone deacetylase inhibitors. Curr Pharm Des. 2008;14(6):529–544.
   PubMed Web of Science ®Google Scholar
• Khan N, Jeffers M, Kumar S, et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J. 2008;409(2):581–589.
   PubMed Web of Science ®Google Scholar
• Bradner JE, Mak R, Tanguturi SK, et al. Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease. Proc Natl Acad Sci USA. 2010;107(28):12617–12622.
   PubMed Web of Science ®Google Scholar
• Dai Y, Sangerman J, Luo HY, et al. Therapeutic fetal-globin inducers reduce transcriptional repression in hemoglobinopathy erythroid progenitors through distinct mechanisms. Blood Cells Mol Dis. 2016;56(1):62–69.
   PubMed Web of Science ®Google Scholar
• Ryan QC, Headlee D, Acharya M, et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol. 2005;23(17):3912–3922.
   PubMed Web of Science ®Google Scholar
• Kummar S, Gutierrez M, Gardner ER, et al. Phase I trial of MS-275, a histone deacetylase inhibitor, administered weekly in refractory solid tumors and lymphoid malignancies. Clin Cancer Res. 2007;13(18 Pt 1):5411–5417.
   PubMed Web of Science ®Google Scholar
• Gojo I, Jiemjit A, Trepel JB, et al. Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias. Blood. 2007;109(7):2781–2790.
   PubMed Web of Science ®Google Scholar
• Gore L, Rothenberg ML, O'Bryant CL, et al. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin Cancer Res. 2008;14(14):4517–4525.
   PubMed Web of Science ®Google Scholar
• Perrine SP, Ginder GD, Faller DV, et al. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the β-globin disorders. N Engl J Med. 1993; 328(2): 81–86.
   PubMed Web of Science ®Google Scholar
• Collins AF, Pearson HA, Giardina P, et al. Oral sodium phenylbutyrate therapy in homozygous β thalassemia: a clinical trial. Blood. 1995;85(1):43–49.
   PubMed Web of Science ®Google Scholar
• Atweh GF, Sutton M, Nassif I, et al. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood. 1999;93(6):1790–1797.
   PubMed Web of Science ®Google Scholar
• Olivieri NF, Rees DC, Ginder GD, et al. Treatment of thalassaemia major with phenylbutyrate and hydroxyurea. Lancet. 1997;350(9076):491–492.
   PubMed Web of Science ®Google Scholar
• Lozzio BB, Lozzio CB, Bamberger EG, Feliu AS. A multipotential leukemia cell line (K-562) of human origin. Proc Soc Exp Biol Med. 1981;166(4):546–550.
   PubMed Web of Science ®Google Scholar
• Rutherford TR, Clegg JB, Weatherall DJ. K562 human leukaemic cells synthesise embryonic haemoglobin in response to haemin. Nature. 1979;280(5718):164–165.
   PubMedGoogle Scholar
• Gambari R, del Senno L, Barbieri R, et al. Human leukemia K-562 cells: induction of erythroid differentiation by 5-azacytidine. Cell Differ. 1984;14(2):87–97.
   PubMedGoogle Scholar
• Cioe L, McNab A, Hubbell HR, et al. Differential expression of the globin genes in human leukemia K562(S) cells induced to differentiate by hemin or butyric acid. Cancer Res. 1981;41(1):237–243.
   PubMed Web of Science ®Google Scholar
• Witt O, Monkemeyer S, Kanbach K, Pekrun A. Induction of fetal hemoglobin synthesis by valproate: modulation of MAP kinase pathways. Am J Hematol. 2002;71(1):45–46.
   PubMed Web of Science ®Google Scholar
• Varsou DD, Nikolakopoulos S, Tsoumanis A, et al. Enalos + KNIME nodes: new cheminformatics tools for drug discovery. Methods Mol Biol. 2018;1824:113–138.
   PubMedGoogle Scholar
• Varsou DD, Nikolakopoulos S, Tsoumanis A, et al. Enalos suite: new cheminformatics platform for drug discovery and computational toxicology. Methods Mol Biol. 2018;1800:287–311.
   PubMedGoogle Scholar